Jazz’s Ziihera Secures 2nd Survival Win to Solidify Its HER2-positive Stomach Cancer Status

Jazz Pharmaceuticals’ Ziihera has achieved a second overall survival win in a Phase 3 trial evaluating first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The results follow Ziihera’s recent FDA approval in the setting and further support its potential as a new standard of care.